The key difference
Phentermine is a sympathomimetic amine (stimulant) that suppresses appetite through norepinephrine release. It’s FDA-approved for short-term use (up to 12 weeks) and has been available since 1959 — one of the longest-standing weight loss medications on the market.
Zepbound (tirzepatide) is a dual GLP-1/GIP receptor agonist — the first in its class. It mimics two gut hormones to reduce appetite, slow gastric emptying, and improve metabolic signaling. FDA-approved in November 2023 for chronic weight management.
These medications serve fundamentally different roles. Phentermine is a short-term tool — fast-acting, inexpensive, and often the first medication prescribed. Zepbound is a long-term treatment that produces the most significant weight loss of any currently available medication. Many patients benefit from both, used sequentially as part of a planned treatment strategy.
Phentermine is a sprint. Zepbound is a marathon. Many patients benefit from both — just not at the same time.
Side-by-side comparison
| Feature | Phentermine | Zepbound |
|---|---|---|
| Drug class | Sympathomimetic amine (stimulant) | Dual GLP-1/GIP receptor agonist |
| Active ingredient | Phentermine HCl | Tirzepatide |
| How taken | Oral tablet, once daily | Weekly subcutaneous injection |
| FDA approved | 1959 | November 2023 |
| Avg weight loss | 5–10% body weight (12 weeks) | Up to 22.5% body weight (72 weeks) |
| Duration of use | Short-term (up to 12 weeks) | Long-term (chronic) |
| Cardiovascular | Increased heart rate (monitor) | Under investigation (SURPASS-CVOT) |
| DEA schedule | Schedule IV controlled substance | Not a controlled substance |
| Insurance coverage | Widely covered; generic (low monthly generic pricing) | Varies; often requires PA |
| Typical cost | low monthly generic pricing (generic) | Insurance or insurance or higher out-of-pocket pricing |
| Main side effects | Insomnia, dry mouth, elevated HR, restlessness | Nausea, diarrhea, constipation |
| Best for | Quick-start appetite suppression, step therapy bridge | Maximum long-term weight loss |
The step therapy connection
Phentermine and Zepbound are often discussed as competing options, but in practice they frequently work together as part of a sequential treatment strategy. Understanding this connection is key to choosing the right weight loss medication.
Many insurance plans require step therapy — documented use of a lower-cost medication before they will approve a GLP-1 or GLP-1/GIP medication like Zepbound. Phentermine’s 12-week course can fulfill this requirement, creating a documented treatment history that supports prior authorization.
This means a phentermine prescription isn’t necessarily an endpoint — it’s often the beginning of a planned treatment pathway. At PEAK, we document treatment outcomes throughout the phentermine course specifically to build the case for GLP-1 coverage when step therapy is required.
- Many insurers require documented use of a lower-cost medication before approving GLP-1s
- Phentermine’s 12-week course can fulfill step therapy requirements
- PEAK documents treatment outcomes to support prior authorization
- This creates a planned treatment pathway, not a failure sequence
At PEAK, we view phentermine as the first chapter, not the whole story. For many patients, a successful phentermine course is the documentation that opens the door to GLP-1 coverage. We plan for this from day one — tracking weight loss, documenting side effects, and building the prior authorization case while you’re actively benefiting from treatment.
When phentermine may be the right starting point
- You want immediate appetite suppression while waiting for GLP-1 approval
- Your insurance requires step therapy documentation
- Cost is a primary concern (low monthly generic pricing vs high out-of-pocket pricing)
- You prefer oral medication and want to start quickly
- You have a shorter-term weight loss goal (event, surgery prep)
Phentermine remains one of the most prescribed weight loss medications in the United States for good reason. It works quickly, costs a fraction of newer medications, and provides meaningful appetite suppression that helps patients build healthier eating habits during the treatment window.
When Zepbound may be the right choice
- You’re seeking maximum possible weight loss
- You need long-term chronic weight management
- You’ve already tried phentermine or other first-line options
- Your insurance covers GLP-1/GIP medications
- You have type 2 diabetes or significant metabolic risk factors
Zepbound represents the most effective weight loss medication currently available based on clinical trial data (SURMOUNT program). Its dual GLP-1/GIP mechanism produces results that exceed any other single-agent treatment in clinical trials, making it the strongest option for patients who need significant, sustained weight reduction.
How we use both medications
PEAK prescribes both phentermine and Zepbound. The right choice depends on your treatment timeline, insurance situation, and weight loss goals.
Many patients follow a planned path: start with phentermine for immediate results and insurance documentation, then transition to a GLP-1/GIP medication like Zepbound for long-term management. This isn’t a failure progression — it’s a treatment strategy that maximizes both your results and your insurance benefits.
Your clinician will evaluate your health history, eating patterns, insurance coverage, and goals to recommend the best starting point. Whether that’s phentermine alone, Zepbound directly, or a planned sequence — every prescription at PEAK serves a purpose.
Boxed warning — thyroid C-cell tumors: GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) carry an FDA boxed warning for thyroid C-cell tumors observed in rodent studies. They are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tell your provider immediately if you notice a lump in your neck, difficulty swallowing, or persistent hoarseness.
